Pharmacogenetics of Ophthalmic Topical Beta-blockers
Overview
Affiliations
Glaucoma is the second leading cause of blindness worldwide. The primary glaucoma risk factor is elevated intraocular pressure. Topical beta-blockers are affordable and widely used to lower intraocular pressure. Genetic variability has been postulated to contribute to interpersonal differences in efficacy and safety of topical beta-blockers. This review summarizes clinically significant polymorphisms that have been identified in the beta-adrenergic receptors (ADRB1, ADRB2 and ADRB3). The implications of polymorphisms in CYP2D6 are also discussed. Although the candidate-gene approach has facilitated significant progress in our understanding of the genetic basis of glaucoma treatment response, most drug responses involve a large number of genes, each containing multiple polymorphisms. Genome-wide association studies may yield a more comprehensive set of polymorphisms associated with glaucoma outcomes. An understanding of the genetic mechanisms associated with variability in individual responses to topical beta-blockers may advance individualized treatment at a lower cost.
Giuffrida E, Platania C, Lazzara F, Conti F, Marcantonio N, Drago F Pharmaceuticals (Basel). 2024; 17(10).
PMID: 39458974 PMC: 11509888. DOI: 10.3390/ph17101333.
Gene therapy for glaucoma: Targeting key mechanisms.
Henderson J, OCallaghan J, Campbell M Vision Res. 2024; 225:108502.
PMID: 39423611 PMC: 11579448. DOI: 10.1016/j.visres.2024.108502.
Opazo-Toro V, Fortuna V, Jimenez W, Pazos Lopez M, Royo M, Ventura-Abreu N Int J Mol Sci. 2023; 24(3).
PMID: 36768422 PMC: 9916755. DOI: 10.3390/ijms24032093.
Yoon D, Kaur R, Gallegos A, West K, Yang H, Schaefer S Am J Clin Dermatol. 2020; 22(1):89-99.
PMID: 33237496 DOI: 10.1007/s40257-020-00567-3.
In vitro and in vivo efficacy of SYL040012, a novel siRNA compound for treatment of glaucoma.
Martinez T, Gonzalez M, Roehl I, Wright N, Paneda C, Jimenez A Mol Ther. 2013; 22(1):81-91.
PMID: 24025749 PMC: 3978804. DOI: 10.1038/mt.2013.216.